IP Library Granted Patent US 7,994,129
Granted Patent B2
US 7,994,129 · App. 11/559,285 · Granted Aug 9, 2011

Methods of using black bear parathyroid hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,994,129
App. No.
11/559,285
Granted
Aug 9, 2011
Kind
B2
Abstract

Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.

Claims (18)

1. A method of increasing cAMP levels in a bone-forming cell comprising contacting the bone-forming cell with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein contacting the bone-forming cell with the polypeptide increases cAMP levels in the bone-forming cell, and wherein the bone-forming cell is in a human subject.

2. The method of claim 1 , wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO:2.

3. The method of claim 1 , wherein the polypeptide comprises SEQ ID NO: 2.

4. A method of reducing apoptosis in a bone-forming cell comprising contacting the bone-forming cell with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein contacting the bone-forming cell with the polypeptide reduces apoptosis in the bone-forming cell, and wherein the bone-forming cell is in a human subject.

5. The method of claim 4 , wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.

6. The method of claim 4 , wherein the polypeptide comprises SEQ ID NO: 2.

7. A method of decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell comprising contacting the bone-forming cell with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein contacting the bone-forming cell with the polypeptide decreases the ratio of expression levels of Bax protein to Bcl-2 protein in the bone-forming cell, and wherein the bone-forming cell is in a human subject.

8. The method of claim 7 , wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.

9. The method of claim 7 , wherein the polypeptide comprises SEQ ID NO: 2.

10. A method of increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell comprising contacting the bone-forming cell with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein contacting the bone-forming cell with the polypeptide increases the expression level of the bone matrix protein, the transcriptional activator, or the transcriptional regulator in the bone-forming cell, and wherein the bone-forming cell is in a human subject.

11. The method of claim 10 , wherein polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.

12. The method of claim 10 , wherein the polypeptide comprises SEQ ID NO: 2.

13. A method of enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a human subject, comprising contacting a bone-forming cell in the human subject with an effective amount of a polypeptide comprising amino acid residues 1-34 of SEQ ID NO: 2, wherein contacting the bone-forming cell with the polypeptide enhances bone mineral density, increases bone mass, decreases bone loss, or reduces the incidence of bone fractures in the human subject.

14. The method of claim 13 , wherein the human subject is a post-menopausal female human afflicted with osteoporosis.

15. The method of claim 13 further comprising administering vitamin D and calcium to the human subject.

16. The method of claim 13 , wherein the polypeptide comprises amino acid residues 1-36 of SEQ ID NO: 2.

17. The method of claim 13 , wherein the polypeptide comprises SEQ ID NO: 2.

18. A method of enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a human subject, comprising contacting a bone-forming cell in the human subject with an effective amount of a polypeptide comprising bear parathyroid hormone or a functional fragment thereof, wherein contacting the bone-forming cell with the polypeptide enhances bone mineral density, increases bone mass, decreases bone loss, or reduces the incidence of bone fractures in the human subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2009
From: BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY
To: MICHIGAN TECHNOLOGICAL UNIVERSITY
Reel/Frame 022694/0387 →
CONFIRMATORY LICENSE Recorded May 23, 2008
From: MICHIGAN TECHNOLOGICAL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020989/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2007
From: DONAHUE, SETH W.
To: BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY
Reel/Frame 019400/0901 →